Testing a new capsule for moderate to severe ulcerative colitis
Part of Digestive system clinical trials.
This trial tests a new medicine, ENC1018, taken by mouth, for people with moderate to severe ulcerative colitis (UC) that hasn't improved with standard treatments. The goal is to see if it's safe and helps reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with ulcerative colitis for at least 3 months, confirmed by a scope or other tests.
- Your UC is moderate to severe, based on a standard scoring system (Mayo score ≥ 6).
- You have tried at least one standard treatment (like mesalamine, steroids, or immune-suppressing drugs) or a biologic (like anti-TNF) and it didn't work well or you couldn't tolerate it.
- If you take oral mesalamine or steroids, your dose must be stable for at least 2 weeks before starting and during the study.
- You are willing to sign a consent form and follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational pill for people with moderate-to-severe ulcerative colitis that has not improved with standard treatments. The goal is to see if the pill can reduce symptoms like bloody stools and frequent bowel movements.
This trial tests an experimental capsule called INT-210 for people with active ulcerative colitis (UC) who haven't improved enough with standard treatments. It aims to see if the drug can help control symptoms and improve the condition.
This trial tests an oral study drug called Hemay005 for people with moderate to severe ulcerative colitis (UC) who have not responded well to other treatments. If you join, you will receive either the study drug or a placebo (inactive pill) to see if it helps reduce symptoms and heal the gut lining.
This trial tests a new oral medication for people with active ulcerative colitis that hasn't responded well to standard treatments. The goal is to see if the drug reduces inflammation and improves symptoms.
This trial tests an experimental drug called PALI-2108 against a placebo (a dummy treatment) for people with moderate to severe ulcerative colitis. It aims to see if PALI-2108 can help reduce symptoms and improve quality of life.
This study tests a new medication (called 627) for people with moderate to severe ulcerative colitis who haven't responded well to or couldn't tolerate other treatments. The goal is to see if it can safely reduce inflammation and improve symptoms.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.